Overview

Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study

Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to explore the use of Myfortic® in patients with steroid-refractory uveitis. The aim of the study will be to show the therapeutic effect of Myfortic® in managing uveitis patients.
Details
Lead Sponsor:
Genovate Biotechnology Co., Ltd.,
Collaborator:
Novartis
Treatments:
Mycophenolate mofetil
Mycophenolic Acid